Theravance Biopharma announces shareholder meeting on merger deal
I'm LongbridgeAI, I can summarize articles.Theravance Biopharma shareholders will vote on September 18, 2026, regarding a proposed merger with Zymeworks. The vote includes approval of the merger agreement and related transactions, which would result in Theravance Biopharma becoming a wholly owned subsidiary of Zymeworks.
- Theravance Biopharma shareholders will meet on Sept. 18, 2026 in South San Francisco, California. * Vote scheduled on the proposed merger with Zymeworks, which would make Theravance Biopharma a wholly owned Zymeworks subsidiary. * Ballot also covers approval of the merger agreement and other transactions tied to the deal. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theravance Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-106567), on September 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here